The pharmaceutical industry has witnessed a dramatic decline in deal activity, reaching its lowest point in nearly a decade as major drugmakers pivot away from commercially ready medicines towards early-stage
The pharmaceutical industry has witnessed a dramatic decline in deal activity, reaching its lowest point in nearly a decade as major drugmakers pivot away from commercially ready medicines towards early-stage






